A Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health
一项针对健康状况良好的成人进行的评估rVSV∆G-MARV-GP疫苗安全性和免疫原性的1期随机、观察者设盲、安慰剂对照、剂量递增临床试验
A Phase 1 Randomized, Observer Blind, Placebo-controlled, Dose-escalation and dose expansion Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health
研究概览
详细说明
This is a observer-blind, Phase 1 Randomized, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health. The study is a dose escalation study that will administer 4 different dose levels to 4 different groups. The lowest dose level will be given and then a safety assessment will occur before escalation to the next dose level. This gradual dosing followed by a safety assessment will be repeated at each dose level.
Approximately 112 participants will be given vaccine (rVSV∆G-MARV-GP) or placebo.
This IAVI C104 study will look at the safety, tolerability and immunogenicity of the rVSV Marburg virus vaccine.
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
District of Columbia
-
Washington D.C.、District of Columbia、美国、20052
- George Washington University
-
-
Kansas
-
Lenexa、Kansas、美国、66219
- Johnson County Clin-Trials
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria
- Adults in good general health
- Participants who are 18 to 50 years of age
- Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study
- Willing to undergo HIV testing, risk reduction counseling, and receive HIV test results
- All sexually active participants must consistently use male or female condoms with all sexual partners for 3 months following IP administration
- All individuals of childbearing potential engaging in sexual activity that could lead to pregnancy must commit to use an effective method of contraception from at least 2 weeks before and continue until 3 months following receipt of vaccine/placebo
- All individuals of childbearing potential must be willing to undergo urine pregnancy tests at time points indicated in the Schedule of Activities (SOA)
- All participants must be willing to forgo donation of blood or any other tissues from screening onward throughout the course of the study
Exclusion Criteria
-
Any clinically relevant abnormality on history or examination including:
history of immunodeficiency or autoimmune disease history of splenectomy history of malignancy in the past 5 years use of corticosteroids, immunosuppressive, anticancer, or other medications considered significant by the Investigator within the previous 6 months body mass index (BMI) ≥ 35.0 kg/m2
-
Any clinically significant acute or chronic medical condition that is considered progressive or in the opinion of the Investigator makes the participant unsuitable for participation in the study
-
Individuals who are pregnant or breastfeeding
-
Bleeding disorder that was diagnosed by a physician
-
Infectious disease: Confirmed HIV-1 or HIV-2 infection, chronic active hepatitis B infection, current hepatitis C infection, active syphilis, or medically diagnosed long COVID 19 Syndrome. Also excluded are participants with active, serious infections requiring parenteral antibiotic, antiviral, or antifungal therapy within 30 days prior to enrollment.
-
Any abnormal laboratory parameters at screening per protocol.
-
Receipt of live attenuated influenza vaccine within the previous 14 days, any other live attenuated vaccine within the previous 30 days or planned receipt within 30 days after vaccination with IP; or receipt of non-live attenuated vaccine within the previous 14 days or planned receipt within 14 days after vaccination with IP, including COVID-19 vaccines
-
Receipt of blood transfusion or blood-derived products within the previous 3 months
-
Prior potential exposure to Marburg Virus, or a medical history of hemorrhagic fever
-
Prior receipt of any VSV-vectored vaccine, any Marburg vaccine, or any vaccine containing a filovirus component. Prior receipt of monoclonal or polyclonal antibodies directed against Marburg or other filovirus in the past 12 months
-
Current participation in another clinical trial, within 3 months prior to enrollment.
-
History of severe local or systemic reactogenicity to vaccines, or severe allergy to food or medications, and/or allergy to any component of this vaccine.
-
Neuropsychiatric condition or substance abuse that compromises safety of the participant and precludes compliance with the protocol
-
Current or planned occupational (medical care, childcare) or household contact (residing in the same household) from screening through 3 months after IP administration with any individual at increased risk from exposure to a live viral vaccine including infants ≤ 1 year of age, adults ≥75 years of age, or immunocompromised individuals.
-
In the opinion of the PI, it is not in the best interest of the participant to participate in the trial
-
A history of long-term treatment (≥ 4 weeks) for arthritis
-
Participants currently experiencing a rash or who have a history of severe, chronic, or frequent rash will be excluded.
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:单组作业
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:rVSV∆G-MARV-GP
|
rVSV∆G-MARV-GP |
|
安慰剂比较:安慰剂/稀释剂
|
Placebo |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Safety and tolerability of rVSV∆G-MARV-GP vaccination: solicited reactogenicity
大体时间:14 Days
|
Occurrence, onset, duration, and severity of local and systemic solicited adverse events within 14 days following vaccination |
14 Days
|
|
Safety and tolerability of rVSV∆G-MARV-GP vaccination: unsolicited reactogenicity
大体时间:28 days
|
Occurrence, onset, duration, severity, and relationship to IP of unsolicited adverse events, including safety laboratory parameters, within 28 days following vaccination |
28 days
|
|
Safety and tolerability of rVSV∆G-MARV-GP vaccination: SAEs and AESIs
大体时间:7 Months
|
Occurrence, onset, duration, severity, and relationship to IP of SAEs and AESIs throughout the study period |
7 Months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
MARV-GP-specific serum antibody responses
大体时间:Throughout the study, up to 6 months after immunisation
|
Proportion of participants with binding antibody responses to MARV-GP |
Throughout the study, up to 6 months after immunisation
|
|
MARV-GP-specific serum antibody responses magnitude and duration
大体时间:Throughout the study, up to 6 months after immunisation
|
Magnitude and duration of binding antibody to MARV-GP throughout the full study period (1 week, 2 weeks, 4 weeks, 2 months, 3 months, 6 months after immunization) |
Throughout the study, up to 6 months after immunisation
|
|
MARV-GP-specific serum antibody neutralization
大体时间:Throughout the study, up to 6 months after immunisation
|
Proportion of participants with neutralizing antibody against Marburg virus as measured by PRNT assay |
Throughout the study, up to 6 months after immunisation
|
|
MARV-GP-specific serum antibody magnitude and duration of neutralization
大体时间:Throughout the study, up to 6 months after immunisation
|
Magnitude and duration of neutralizing antibody against Marburg virus as measured by PRNT assay throughout the full study period (1 week, 2 weeks, 4 weeks, 2 months, 3 months, 6 months after immunization) |
Throughout the study, up to 6 months after immunisation
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.